Sabrina Khan1, Astrid Olesen1, Messoud Ashina1. 1. Danish Headache Center, Dept. of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
Abstract
INTRODUCTION: Migraine and cluster headache are challenging to manage, with no tailored preventive medications available. Targeting the calcitonin gene-related peptide (CGRP) pathway to treat these headaches may be the first focused therapeutic option to date, with the potential for promising efficacy. METHODS: We systematically searched PubMed and clinicaltrials.gov for randomized controlled trials investigating the preventive potential of monoclonal antibodies against the CGRP pathway in the treatment of migraine and cluster headache. RESULTS: The literature search returned a total of 136 records, of which 32 were eligible for review. DISCUSSION: Clinical data from phase II and III trials of the four monoclonal antibodies targeting the CGRP pathway: Eptinezumab, erenumab, fremanezumab, and galcanezumab, collectively show a positive effect in the preventive treatment of episodic and chronic migraine. Multiple phase II and III trials are under way to further determine the efficacy and safety of this new drug class. It may be particularly important to assess the cardiovascular effects of long-term CGRP blockade. Phase III trials are also currently in progress for the preventive treatment of cluster headache. CONCLUSION: Efficacy of anti-CGRP monoclonal antibodies spells a promising future for the many patients suffering from migraine, and possibly also for the smaller but severely-affected population with cluster headache.
INTRODUCTION:Migraine and cluster headache are challenging to manage, with no tailored preventive medications available. Targeting the calcitonin gene-related peptide (CGRP) pathway to treat these headaches may be the first focused therapeutic option to date, with the potential for promising efficacy. METHODS: We systematically searched PubMed and clinicaltrials.gov for randomized controlled trials investigating the preventive potential of monoclonal antibodies against the CGRP pathway in the treatment of migraine and cluster headache. RESULTS: The literature search returned a total of 136 records, of which 32 were eligible for review. DISCUSSION: Clinical data from phase II and III trials of the four monoclonal antibodies targeting the CGRP pathway: Eptinezumab, erenumab, fremanezumab, and galcanezumab, collectively show a positive effect in the preventive treatment of episodic and chronic migraine. Multiple phase II and III trials are under way to further determine the efficacy and safety of this new drug class. It may be particularly important to assess the cardiovascular effects of long-term CGRP blockade. Phase III trials are also currently in progress for the preventive treatment of cluster headache. CONCLUSION: Efficacy of anti-CGRP monoclonal antibodies spells a promising future for the many patients suffering from migraine, and possibly also for the smaller but severely-affected population with cluster headache.
Authors: Anne Luise H Vollesen; Agneta Snoer; Rasmus P Beske; Song Guo; Jan Hoffmann; Rigmor H Jensen; Messoud Ashina Journal: JAMA Neurol Date: 2018-10-01 Impact factor: 18.302
Authors: Susan P Mollan; Jasvir S Virdee; Edward J Bilton; Mark Thaller; Anita Krishan; Alexandra J Sinclair Journal: Eye (Lond) Date: 2021-02-12 Impact factor: 4.456
Authors: Alexei A Kamshilin; Maxim A Volynsky; Olga Khayrutdinova; Dilyara Nurkhametova; Laura Babayan; Alexander V Amelin; Oleg V Mamontov; Rashid Giniatullin Journal: J Headache Pain Date: 2018-06-18 Impact factor: 7.277
Authors: Messoud Ashina; Joel Saper; Roger Cady; Barbara A Schaeffler; David M Biondi; Joe Hirman; Susan Pederson; Brent Allan; Jeff Smith Journal: Cephalalgia Date: 2020-02-19 Impact factor: 6.292
Authors: Peter J Goadsby; Stewart J Tepper; Paul B Watkins; Girma Ayele; Rosa Miceli; Matthew Butler; Lawrence Severt; Michelle Finnegan; Armin Szegedi; Joel M Trugman; Abhijeet Jakate Journal: Cephalalgia Date: 2019-09-19 Impact factor: 6.292